Data from the landmark study that earned Herceptin® approval in 1998 by the Food and Drug Administration (FDA) for the treatment of metastatic breast cancer were published in the New England Journal of Medicine on 15 March 2001.
The study shows that Herceptin increases overall response rate to treatment, slows progression of metastatic breast disease, and increases overall survival for patients given the drug along with standard chemotherapy compared to chemotherapy alone. The newly published report extends the study's followup through October 1999.
Herceptin (trastuzumab) is a monoclonal antibody designed in the laboratory that targets a genetic defect found in some cancer cells. "This is the beginning of an important new era in cancer treatment, since many more such targeted therapies are now undergoing clinical evaluation," wrote Elizabeth Eisenhauer, M.D., Queens University, in an editorial accompanying the journal article.
Current Clinical Trials of Herceptin:
Herceptin and Breast Cancer
Hereceptin and Other Cancers
Related articles on Herceptin:
Questions and Answers About Herceptin® (Trastuzumab)
Herceptin® Provides Overall Survival Benefit When Added to Chemotherapy for the Treatment of Metastatic Breast Cancer (May 15, 1999)
Two New Trials To Test Herceptin® in Non-Metastatic Breast Cancer